New Biotech IPO Pasithea Therapeutics Looks To Bring Investment Into Mental Health

Pasithea Therapeutics partnered with IV Doc to provide in-home ketamine treatments in the United States to consumers with clinical depression and anxiety, and with Zen Healthcare to provide clinic-based ketamine treatment for depression in the United Kingdom. Through clinics in the United Kingdom and at-home services in the United States, Pasithea seeks to gain deeper knowledge on the effects of ketamine Infusion therapy to treat depression.

Pasithea Therapeutics Corp. is a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. The biotech operations will focus on developing drugs . . .